Bank of America
BBIO icon

Bank of America’s BridgeBio Pharma BBIO Stock Holding History

Bank of America’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-22,400
Closed -$1.59M – 7417
2020
Q4 		$1.59M Buy
+22,400
New +$1.08M ﹤0.01% 4138

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America's BBIO Position: Q1 2026 in Review

Bank of America increased its BridgeBio Pharma (BBIO) stake by 19% in Q1 2026, buying an estimated $15.1M and bringing the position to 1,285,748 shares worth $95.5M. The position accounts for 0.01% of the portfolio, ranked #1155.

Bank of America first reported a position in BBIO in Q3 2019 and has held it in 27 quarters since. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Bank of America held 1,285,748 shares of BridgeBio Pharma worth $95.5M as of Q1 2026.
  • Bank of America bought 207,700 BridgeBio Pharma shares in Q1 2026, an estimated $15.1M.
  • BridgeBio Pharma made up 0.01% of Bank of America's portfolio in Q1 2026, its #1155 holding.
  • Bank of America first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 27 quarters since.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.